Compare Capri Holdings Ltd (CPRI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Smith & Nephew plc — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while Smith & Nephew plc trades at $27.17 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 6.6× Capri Holdings Ltd's market cap, and Smith & Nephew plc pays a 2.95% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Smith & Nephew plc for 120 Days on average.
| CPRI | SNN | |
|---|---|---|
Market Cap | $1.67B | $11.10B |
Volume | 3,722,279 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $37.17 |
52-Week Low | $12.71 | $26.42 |
Typical Hold Time | 41 Days | 120 Days |
Enterprise Value | $2.95B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with strong profitability metrics (62.71% gross margin, 252.89% ROE) but concerning fundamental trends including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo brands.
The investment case balances attractive valuation (P/S 0.51) against substantial operational challenges. Analyst consensus leans neutral with a $20.57 price target representing 42% upside, but investors face risks from continued revenue declines, high debt levels, and the ongoing Michael Kors turnaround execution. The stock offers potential value if management's growth initiatives gain traction in the second half of 2026.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
